Product Code: 55927
The blood glucose monitoring market is expected to register a CAGR of 9.6% during the forecast period of 2021-2026. The market is estimated to reach a value of USD 27.2 billion by 2026, which is due to an increase in the usage of monitoring devices among the type-2 diabetes population. Blood glucose monitoring devices are used for effective diabetes diagnosis and treatment. A rise in the diabetic population drives the market by increasing the use of blood glucose monitoring devices. Obesity is also considered as one of the major factors contributing to the disease, primarily Type 2 diabetes. Also, other factors, such as technological innovations and advancements, give many conveniences in measuring blood glucose levels. One such advancement in monitoring the blood glucose level is established with continuous glucose monitoring devices. These devices help in the early detection of hypo and hyperglycemic conditions. This favor is expected to drive the market for glucose monitoring.
Key Market Trends
Glucometer consumables occupy highest market share
Although CGM is an advanced way for people living with diabetes to check glucose readings in real-time, SMBG is the most preferred device by the patients due to its economic affordability and less sophisticated usage when compared to CGM. The SBGM devices occupy more than 68% of the share in the blood glucose monitoring market. The growth in market volume and share of test strips are expected to be higher than that of glucose meters, because of the difference in use-case frequency. The average efficiency of the glucose meter ranges between six months to three years, whereas test strips are for one-time use. The introduction of new kinds of lancet devices that induce lesser pain to the users is expected to help the market's growth, as the acceptance rate is expected to rise during the forecast period.
North America is leading the market
In 2020, North America, especially the United States, held the largest share in the blood glucose monitoring market, due to the large patient pool and wide acceptance of advanced technologies followed by Europe, with moderate growth. As per the American Diabetes Association (ADA), in 2018, 34.2 million Americans, or 10.5% of the population, had diabetes. Nearly 1.6 million Americans have type 1 diabetes, including about 187,000 children and adolescents. In the United States, there are new innovations from start-up companies having approximately 2.9 billion funding in diabetes industries, like Glooko, OneDrop, verily, Vacate, Insulet, Noom, Bigfoot Biomedical, Virta Health, Diabeloop, Orgenesis, etc. and Companies joined together in diabetes field to bring new technologies are increasing the market in the forecasting period, for instance, In July 2020, Medtronic PLC and Tandem Diabetes Care Inc. announced that they entered into a non-exclusive patent cross-license agreement for certain technologies in the field of diabetes.
Competitive Landscape
The blood glucose monitoring market is highly fragmented, with few major manufacturers present in the market. Mergers and acquisitions among the players in the recent past helped the companies to strengthen their market presence. For example, In September 2020, Insulet Corporation, with its Omnipod Insulin Management System (Omnipod System), announced it is commercially launching its Omnipod DASH Insulin Management System (Omnipod DASH System) in additional countries. The Omnipod DASH System is now available in Sweden, Finland, Norway, and Denmark and will be offered in France, Belgium, Germany, Austria, Switzerland, and Israel in the coming weeks.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 Study Assumptions
- 1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Drivers
- 4.3 Restraints
- 4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 Self-monitoring blood glucose devices (Value and Volume, 2016 - 2026)
- 5.1.1 By Component
- 5.1.1.1 Glucometer Devices
- 5.1.1.2 Test Strips
- 5.1.1.3 Lancets
- 5.2 Continuous blood glucose monitoring devices (Value and Volume, 2016 - 2026)
- 5.2.1 By Component
- 5.2.1.1 Sensors
- 5.2.1.2 Durables (Receivers and Transmitters)
- 5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States (Value and Volume, 2016 - 2026)
- 5.3.1.1.1 Self-monitoring Blood Glucose Devices
- 5.3.1.1.1.1 By Component (Glucometer Device, Test strips, Lancets)
- 5.3.1.1.2 Continuous Glucose Monitoring devices
- 5.3.1.1.2.1 By Component (Sensors and Receivers)
- 5.3.1.2 Canada (Value and Volume, 2016 - 2026)
- 5.3.1.2.1 Self-monitoring blood glucose devices
- 5.3.1.2.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.1.2.2 Continuous Glucose Monitoring
- 5.3.1.2.2.1 By Component (Sensors and Receivers)
- 5.3.1.3 Rest of North America (Value and Volume, 2016 - 2026)
- 5.3.1.3.1 Self-monitoring blood glucose devices
- 5.3.1.3.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.1.3.2 Continuous Glucose Monitoring
- 5.3.1.3.2.1 By Component (Sensors and Receivers)
- 5.3.2 Europe
- 5.3.2.1 France (Value and Volume, 2016 - 2026)
- 5.3.2.1.1 Self-monitoring Blood Glucose Devices
- 5.3.2.1.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.2.1.2 Continuous Glucose Monitoring
- 5.3.2.1.2.1 By Component (Sensors and Receivers)
- 5.3.2.2 Germany (Value and Volume, 2016 - 2026)
- 5.3.2.2.1 Self-monitoring Blood Glucose Devices
- 5.3.2.2.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.2.2.2 Continuous Glucose Monitoring
- 5.3.2.2.2.1 By Component (Sensors and Receivers)
- 5.3.2.3 Italy (Value and Volume, 2016 - 2026)
- 5.3.2.3.1 Self-monitoring blood glucose devices
- 5.3.2.3.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.2.3.2 Continuous Glucose Monitoring
- 5.3.2.3.2.1 By Component (Sensors and Receivers)
- 5.3.2.4 Spain (Value and Volume, 2016 - 2026)
- 5.3.2.4.1 Self-monitoring blood glucose devices
- 5.3.2.4.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.2.4.2 Continuous Glucose Monitoring
- 5.3.2.4.2.1 By Component (Sensors and Receivers)
- 5.3.2.5 United Kingdom (Value and Volume, 2016 - 2026)
- 5.3.2.5.1 Self-monitoring blood glucose devices
- 5.3.2.5.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.2.5.2 Continuous Glucose Monitoring
- 5.3.2.5.2.1 By Component (Sensors and Receivers)
- 5.3.2.6 Russia (Value and Volume, 2016 - 2026)
- 5.3.2.6.1 Self-monitoring blood glucose devices
- 5.3.2.6.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.2.6.2 Continuous Glucose Monitoring
- 5.3.2.6.2.1 By Component (Sensors and Receivers)
- 5.3.2.7 Rest of Europe (Value and Volume, 2016 - 2026)
- 5.3.2.7.1 Self-monitoring blood glucose devices
- 5.3.2.7.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.2.7.2 Continuous Glucose Monitoring
- 5.3.2.7.2.1 By Component (Sensors and Receivers)
- 5.3.3 Latin America
- 5.3.3.1 Mexico (Value and Volume, 2016 - 2026)
- 5.3.3.1.1 Self-monitoring Blood Glucose Devices
- 5.3.3.1.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.3.1.2 Continuous Glucose Monitoring
- 5.3.3.1.2.1 By Component (Sensors and Receivers)
- 5.3.3.2 Brazil (Value and Volume, 2016 - 2026)
- 5.3.3.2.1 Self-monitoring Blood Glucose Devices
- 5.3.3.2.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.3.2.2 Continuous Glucose Monitoring
- 5.3.3.2.2.1 By Component (Sensors and Receivers)
- 5.3.3.3 Rest of Latin America (Value and Volume, 2016 - 2026)
- 5.3.3.3.1 Self-monitoring Blood Glucose Devices
- 5.3.3.3.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.3.3.2 Continuous Glucose Monitoring
- 5.3.3.3.2.1 By Component (Sensors and Receivers)
- 5.3.4 Asia-Pacific
- 5.3.4.1 Japan (Value and Volume, 2016 - 2026)
- 5.3.4.1.1 Self-monitoring Blood Glucose Devices
- 5.3.4.1.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.1.2 Continuous Glucose Monitoring
- 5.3.4.1.2.1 By Component (Sensors and Receivers)
- 5.3.4.2 South Korea (Value and Volume, 2016 - 2026)
- 5.3.4.2.1 Self-monitoring Blood Glucose Devices
- 5.3.4.2.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.2.2 Continuous Glucose Monitoring
- 5.3.4.2.2.1 By Component (Sensors and Receivers)
- 5.3.4.3 China (Value and Volume, 2016 - 2026)
- 5.3.4.3.1 Self-monitoring Blood Glucose Devices
- 5.3.4.3.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.3.2 Continuous Glucose Monitoring
- 5.3.4.3.2.1 By Component (Sensors and Receivers)
- 5.3.4.4 India (Value and Volume, 2016 - 2026)
- 5.3.4.4.1 Self-monitoring Blood Glucose Devices
- 5.3.4.4.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.4.2 Continuous Glucose Monitoring
- 5.3.4.4.2.1 By Component (Sensors and Receivers)
- 5.3.4.5 Australia (Value and Volume, 2016 - 2026)
- 5.3.4.5.1 Self-monitoring Blood Glucose Devices
- 5.3.4.5.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.5.2 Continuous Glucose Monitoring
- 5.3.4.5.2.1 By Component (Sensors and Receivers)
- 5.3.4.6 Vietnam (Value and Volume, 2016 - 2026)
- 5.3.4.6.1 Self-monitoring Blood Glucose Devices
- 5.3.4.6.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.6.2 Continuous Glucose Monitoring
- 5.3.4.6.2.1 By Component (Sensors and Receivers)
- 5.3.4.7 Malaysia (Value and Volume, 2016 - 2026)
- 5.3.4.7.1 Self-monitoring Blood Glucose Devices
- 5.3.4.7.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.7.2 Continuous Glucose Monitoring
- 5.3.4.7.2.1 By Component (Sensors and Receivers)
- 5.3.4.8 Indonesia (Value and Volume, 2016 - 2026)
- 5.3.4.8.1 Self-monitoring Blood Glucose Devices
- 5.3.4.8.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.8.2 Continuous Glucose Monitoring
- 5.3.4.8.2.1 By Component (Sensors and Receivers)
- 5.3.4.9 Philippines (Value and Volume, 2016 - 2026)
- 5.3.4.9.1 Self-monitoring Blood Glucose Devices
- 5.3.4.9.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.9.2 Continuous Glucose Monitoring
- 5.3.4.9.2.1 By Component (Sensors and Receivers)
- 5.3.4.10 Thailand (Value and Volume, 2016 - 2026)
- 5.3.4.10.1 Self-monitoring Blood Glucose Devices
- 5.3.4.10.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.10.2 Continuous Glucose Monitoring
- 5.3.4.10.2.1 By Component (Sensors and Receivers)
- 5.3.4.11 Rest of Asia-Pacific (Value and Volume, 2016 - 2026)
- 5.3.4.11.1 Self-monitoring Blood Glucose Devices
- 5.3.4.11.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.11.2 Continuous Glucose Monitoring
- 5.3.4.11.2.1 By Component (Sensors and Receivers)
- 5.3.5 Middle-East and Africa
- 5.3.5.1 Saudi Arabia (Value and Volume, 2016 - 2026)
- 5.3.5.1.1 Self-monitoring Blood Glucose Devices
- 5.3.5.1.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.5.1.2 Continuous Glucose Monitoring
- 5.3.5.1.2.1 By Component (Sensors and Receivers)
- 5.3.5.2 Iran (Value and Volume, 2016 - 2026)
- 5.3.5.2.1 Self-monitoring Blood Glucose Devices
- 5.3.5.2.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.5.2.2 Continuous Glucose Monitoring
- 5.3.5.2.2.1 By Component (Sensors and Receivers)
- 5.3.5.3 Egypt (Value and Volume, 2016 - 2026)
- 5.3.5.3.1 Self-monitoring Blood Glucose Devices
- 5.3.5.3.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.5.3.2 Continuous Glucose Monitoring
- 5.3.5.3.2.1 By Component (Sensors and Receivers)
- 5.3.5.4 Oman (Value and Volume, 2016 - 2026)
- 5.3.5.4.1 Self-monitoring Blood Glucose Devices
- 5.3.5.4.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.5.4.2 Continuous Glucose Monitoring
- 5.3.5.4.2.1 By Component (Sensors and Receivers)
- 5.3.5.5 South Africa (Value and Volume, 2016 - 2026)
- 5.3.5.5.1 Self-monitoring Blood Glucose Devices
- 5.3.5.5.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.5.5.2 Continuous Glucose Monitoring
- 5.3.5.5.2.1 By Component (Sensors and Receivers)
- 5.3.5.6 Rest of Middle-East and Africa (Value and Volume, 2016 - 2026)
- 5.3.5.6.1 Self-monitoring Blood Glucose Devices
- 5.3.5.6.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.5.6.2 Continuous Glucose Monitoring
- 5.3.5.6.2.1 By Component (Sensors and Receivers)
6 MARKET INDICATORS
- 6.1 Type-1 Diabetes population (2016 - 2026)
- 6.2 Type-2 Diabetes population (2016 - 2026)
7 COMPETITIVE LANDSCAPE
- 7.1 COMPANY PROFILES
- 7.1.1 Abbott Diabetes Care
- 7.1.2 Roche Holding AG
- 7.1.3 LifeScan
- 7.1.4 Dexcom Inc.
- 7.1.5 Medtronic PLC
- 7.1.6 Arkray Inc.
- 7.1.7 Ascensia Diabetes Care
- 7.1.8 Agamatrix Inc.
- 7.1.9 Bionime Corporation
- 7.1.10 Acon Laboratories Inc.
- 7.1.11 Medisana AG
- 7.1.12 Trivida Functional Medicine
- 7.1.13 Rossmax International Ltd
- 7.1.14 Senseonics
- 7.2 COMPANY SHARE ANALYSIS
- 7.2.1 Self-monitoring Blood Glucose Devices
- 7.2.1.1 Abbott Diabetes Care
- 7.2.1.2 Roche Holding AG
- 7.2.1.3 LifeScan
- 7.2.1.4 Others
- 7.2.2 Continuous Glucose Monitoring Devices
- 7.2.2.1 Dexcom Inc.
- 7.2.2.2 Medtronic PLC
- 7.2.2.3 Abbott Diabetes Care
- 7.2.2.4 Others
8 MARKET OPPORTUNITIES AND FUTURE TRENDS